Post-earnings recap
Reported
Tue, May 18, 2021
EPS actual
$-0.30
EPS est.
$-0.38
EPS surprise
+20.42%
1-day move
+14.24%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Legend Biotech's earnings report showed a positive surprise in EPS, which contributed to a strong stock reaction, rising 14.24%. Investors may be encouraged by the management's comments on clinical progress, even though no specific guidance was given. The lack of revenue data leaves some uncertainty, but the EPS beat suggests better-than-expected performance in their operations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.30 | N/A | +20.42% |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about ongoing projects. They noted significant advancements but refrained from offering specific future guidance.
Management highlighted progress in clinical trials.
They emphasized the importance of upcoming data releases.
No specific guidance was provided for future quarters.